secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2022-05-23T23:59:59+00:00
Accession:  0001516551-22-000013
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye Bioscience secures support agreements from Emerald Health Sciences for EHT acquisition; director resigns
--------------------------------------------------------------------------------

- Emerald Health Sciences (EHS) agreed to vote its EHT shares in favor of the arrangement and against any alternative proposal.
- EHS also agreed to vote its Skye shares in favor of adopting the arrangement agreement.
- Jim Heppell resigned as director and from all committees effective May 18, 2022, with no disagreement.
- Support agreements terminate upon termination of the arrangement agreement.
- Transaction was previously announced on May 11, 2022, and is subject to shareholder and regulatory approvals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000151655122000013/0001516551-22-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000151655122000013/skye-20220518.htm
  HTML page:      https://secwatch.observer/filing/0001516551-22-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer